Article Details

Akebia Therapeutics (AKBA) Earns Neutral Rating from Analysts at Citigroup

Retrieved on: 2019-03-22 20:07:12

Tags for this article:

Click the tags to see associated articles and topics

Akebia Therapeutics (AKBA) Earns Neutral Rating from Analysts at Citigroup. View article details on hiswai:

Excerpt

<div><b>Baupost Group</b> LLC MA purchased a new position in Akebia Therapeutics in the fourth quarter worth $135,327,000. BlackRock Inc. raised its position ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up